161 related articles for article (PubMed ID: 19954359)
1. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.
Rottiers P; De Smedt T; Steidler L
Int Rev Immunol; 2009; 28(6):465-86. PubMed ID: 19954359
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation by genetically engineered lactic acid bacteria.
Van Huynegem K; Loos M; Steidler L
Front Biosci (Landmark Ed); 2009 Jun; 14(13):4825-35. PubMed ID: 19482589
[TBL] [Abstract][Full Text] [Related]
3. Delivery of therapeutic proteins through Lactococcus lactis.
Neirynck S; Steidler L
Biotechnol Genet Eng Rev; 2006; 22():253-66. PubMed ID: 18476334
[No Abstract] [Full Text] [Related]
4. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
[TBL] [Abstract][Full Text] [Related]
5. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.
Vandenbroucke K; Hans W; Van Huysse J; Neirynck S; Demetter P; Remaut E; Rottiers P; Steidler L
Gastroenterology; 2004 Aug; 127(2):502-13. PubMed ID: 15300583
[TBL] [Abstract][Full Text] [Related]
6. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.
Termont S; Vandenbroucke K; Iserentant D; Neirynck S; Steidler L; Remaut E; Rottiers P
Appl Environ Microbiol; 2006 Dec; 72(12):7694-700. PubMed ID: 17028239
[TBL] [Abstract][Full Text] [Related]
7. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug delivery by genetically modified Lactococcus lactis.
Steidler L; Rottiers P
Ann N Y Acad Sci; 2006 Aug; 1072():176-86. PubMed ID: 17057198
[TBL] [Abstract][Full Text] [Related]
9. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins.
Bermúdez-Humarán LG
Hum Vaccin; 2009 Apr; 5(4):264-7. PubMed ID: 19202351
[TBL] [Abstract][Full Text] [Related]
10. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
11. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
12. Churning out safer microbes for drug delivery.
Syvanen M
Nat Biotechnol; 2003 Jul; 21(7):758-9. PubMed ID: 12833095
[No Abstract] [Full Text] [Related]
13. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
14. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
[TBL] [Abstract][Full Text] [Related]
15. [Construction of Lactococcus lactis expression vector of recombinant human trefoil factor family 2].
Xing R; Yang XQ; Chen XQ; Zhang ZS
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1280-3. PubMed ID: 16982435
[TBL] [Abstract][Full Text] [Related]
16. A review on Lactococcus lactis: from food to factory.
Song AA; In LLA; Lim SHE; Rahim RA
Microb Cell Fact; 2017 Apr; 16(1):55. PubMed ID: 28376880
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
18. In situ delivery of cytokines by genetically engineered Lactococcus lactis.
Steidler L
Antonie Van Leeuwenhoek; 2002 Aug; 82(1-4):323-31. PubMed ID: 12369199
[TBL] [Abstract][Full Text] [Related]
19. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
20. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation.
Villatoro-Hernandez J; Montes-de-Oca-Luna R; Kuipers OP
Expert Opin Biol Ther; 2011 Mar; 11(3):261-7. PubMed ID: 21204744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
